Alvogen · 3 hours ago
Associate Director Clinical Research & Develo
Alvogen is focused on the clinical development of 505(b)(2) products and complex generics. The successful candidate will act as an independent clinical pharmacologist, providing clinical strategies and collaborating with various departments to ensure successful execution of clinical studies.
Health CareManufacturingMedicalPharmaceutical
Responsibilities
Assess viability of 505(b)(2) and complex generics ideas from Clinical R&D perspective
Act as an independent clinical pharmacologist to identify required studies per the regulatory strategy, and to design and execute such studies
Responsible for providing clinical expertise pertaining to study design, planning and execution of Phase 1, Phase 2 or Phase 3 clinical studies
Ensures each project has a robust PK and clinical program and adheres to GCP, GLP and all applicable regulatory guidelines. Monitor changes/updates made to Guidance documents related to Clinical studies/BE studies and implementation thereof
Identify gaps in pre-clinical and Phase 1 DDP that could impact Phase 2/3 design and execution timelines for Alvogen internal projects as well as programs being evaluated as part of due diligence
Drafting of initial pediatric study plan (iPSP) and clinical sections of the regulatory submissions (eg. pIND, Type A/B/C/D meetings, NDA, etc.) for 505b(2) products
Partner with Regulatory Affairs for FDA meetings ensure successful execution of 505(b)(2) programs
Collaborate with R&D during product development to provide guidance on PK issues, developing biorelevant dissolution, PK modeling, simulations, WinNonlin, and IVIVC/IVIVR models
Collaborate extensively with Portfolio and Business Development and provide scientific feedback and clinical plans for identifying and developing new products through in-licensing or due diligence efforts
Works cross-functionally and with external partners to select clinical study designs to align with Company objectives; Works with Regulatory in filing of applications and responding to deficiencies
Qualification
Required
Ph.D in a scientific discipline with at least 10 years of experience in the conduct of PK, clinical end point, and Phase 2/3 studies
Experience in generic/specialty pharmaceutical companies on a variety of dosage forms, including inhalation, topical, and complex injectable products is required
Clinical development experience with 505b(2) products is required
Thorough knowledge and understanding of scientific principles applicable to product development and extensive experience in PK modeling, simulation, IVIVC/IVIVR to support product development
Extensive knowledge of clinical development, including thorough understanding of the clinical development phases, processes and techniques used to execute a clinical development program
Knowledge of GCP, GLP, ICH and regulatory guidelines is essential
Excellent written and verbal communications and interpersonal skills
Proven strong leadership and management skills; can work across a portfolio with competing priorities
Team player with proven flexibility; high degree of motivation
Self-starter; can work with limited direction
Strong analytical skills
Strong hands-on, 'roll up your sleeves' and 'right first time' mentality
Ability to think strategically and execute on strategy
Preferred
Experience in CNS/Psychiatric therapeutics area (e.g., MDD, Schizophrenia, etc.)
Company
Alvogen
Alvogen develops, manufactures, and markets pharmaceutical products, including generics and injectables.
Funding
Current Stage
Late StageTotal Funding
$769MKey Investors
Aztiq Pharma Partners
2025-09-23Acquired
2025-03-07Debt Financing· $669M
2021-06-30Private Equity· $100M
Recent News
2025-11-10
2025-09-27
Morningstar.com
2025-09-26
Company data provided by crunchbase